A Study to Assess Anktiva in Patients With Long Covid-19. (INTERRUPT_LC)

[Mij]

Official Title
Interleukin-15 Superagonist Nogapendekin Alfa Inbakicept in Participants With Long Covid

Brief Summary
This study will test the safety and tolerability of Anktiva in patients with Long Covid. Eligible patients will receive up to 2 doses of Anktiva and have follow-up exams and tests.

Study Contact
Name: Kamin Personett

Phone Number: 12673777737

Email: kamin.personett@immunitybio.com

California Locations
San Francisco, California, United States, 94110

University of California - San Francisco
Contact :
Emily Fehrman
(650) 761-2163 Emily.Fehrman2@ucsf.edu
Principal Investigator :
Michael Peluso, MD

 

[Mij]

A new PostCOVID/LongCOVID single-arm study by ImmunityBio of Anktiva, an interleukin-15 receptor agonist which is used to treat bladder cancer.

20 patients will be enrolled at UCSF in San Francisco, with the study planned to start this month.